Volcano Capital

Health Biotech is a research and development firm focused on precision medicine through the application of mass spectrometry technology. The company specializes in creating comprehensive detection solutions that include tools, equipment, and reagent consumables. Its innovative technology employs liquid chromatography-mass spectrometry to facilitate the early diagnosis, treatment, and monitoring of Alzheimer's disease. By quantitatively detecting specific biomarkers, such as "ipilin," Health Biotech enables healthcare professionals to assess Alzheimer's risk and provide targeted interventions aimed at delaying disease onset and enhancing cognitive function in patients. Through its commitment to advancing mass spectrometry applications, Health Biotech strives to deliver reliable services and improve patient outcomes in the realm of neurological health.

Summit Access develops surgical micro-access kits designed to facilitate a simplified and protected approach to peripheral vascular access and interventional procedures. The kits include a tapered, expandable, self-blunting needle and custom-tapered guidewires or guidelines, enabling medical practitioners to perform interventional radiology, interventional cardiology, and vascular surgery with greater efficiency and safety.

MediQuire Inc. is a technology company focused on providing innovative solutions for community health centers. Founded in 2013 and based in New York, the company specializes in offering a range of services, from basic reporting tools to comprehensive population management and risk management suites. MediQuire's platform is designed to enhance understanding of patient outcomes by integrating medical, behavioral, financial, and social data, thus enabling advanced analytics. This approach aims to improve the health of the Medicaid population while simultaneously reducing costs. The company caters to a diverse clientele, including federally qualified health centers, health center control networks, primary care associations, and quality improvement associations, ensuring that its technology solutions are tailored to meet the specific needs of various health organizations.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

EndoShape, Inc. is a medical device company based in Boulder, Colorado, established in 2006. The company specializes in the development and commercialization of minimally invasive devices utilizing proprietary shape memory polymer technology for various vascular applications. EndoShape's product offerings include a multi-coil system designed for arterial and venous embolizations within the peripheral vasculature, addressing both vascular and nonvascular medical needs. With a focus on innovation, EndoShape aims to enhance treatment options in the embolization and occlusion markets.

Mercator MedSystems develops catheter-guided microfluid injection systems for site-specific delivery of therapeutic agents directly across various blood vessels. Its products include Cricket and Bullfrog micro-infusion catheters, designed to inject therapeutic agents directly into deep tissues without systemic delivery. The company's technology enables targeted treatments for vascular diseases, oncology, and regenerative medicine.

HydroCision develops, manufactures, and markets fluid jet based surgical tools for minimally invasive spine surgery. Its products include the SpineJet HydroSurgery System for tissue ablation and removal, SpineJet HydroDiscectomy Systems for minimally invasive discectomy procedures, and AlloJet systems for bone allograft preparation. The company serves hospitals and physicians through sales representatives.

VisionSense is a company focused on developing innovative visualization solutions for minimally invasive surgery (MIS). By utilizing advanced sensor technology and proprietary software, VisionSense provides a system that offers natural stereoscopic sight, delivering depth perception and 3D-HD resolution images. This technology allows for maneuvering flexibility through the smallest access points, addressing the limitations of traditional 2D (monocular) imaging that often hinders a surgeon's perspective. With enhanced tissue understanding and improved hand-eye coordination, surgeons are empowered to perform more complex procedures with greater confidence, particularly when using advanced articulating surgical tools.